QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Coherus BioSciencesKrystal BiotechPassage BioVaxcyteCellectis
SymbolNASDAQ:CHRSNASDAQ:KRYSNASDAQ:PASGNASDAQ:PCVXNASDAQ:CLLS
Price Information
Current Price$16.23$81.11$18.85$25.84$22.47
52 Week RangeBuyBuyBuyBuyHold
MarketRank™
Overall Score1.41.31.91.80.8
Analysis Score3.42.54.33.51.2
Community Score2.52.53.03.22.9
Dividend Score0.00.00.00.00.0
Ownership Score0.01.71.71.70.0
Earnings & Valuation Score1.30.00.60.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$28.50$97.20$25.24$48.00$24.25
% Upside from Price Target75.60% upside19.84% upside33.92% upside85.76% upside7.92% upside
Trade Information
Market Cap$1.17 billion$1.60 billion$865.54 million$1.32 billion$954.66 million
Beta1.571.2N/AN/A2.59
Average Volume1,442,923170,173545,513358,864459,970
Sales & Book Value
Annual Revenue$356.07 millionN/AN/AN/A$22.99 million
Price / Sales3.28N/AN/AN/A41.53
Cashflow$1.21 per shareN/AN/AN/AN/A
Price / Cash13.36N/AN/AN/AN/A
Book Value$1.50 per share$11.72 per shareN/AN/A$8.37 per share
Price / Book10.82N/AN/AN/A2.68
Profitability
Net Income$89.83 million$-19,090,000.00N/A$-50,270,000.00$-102,090,000.00
EPS$1.23($1.20)N/AN/A($2.41)
Trailing P/E Ratio7.96N/A0.000.00N/A
Forward P/E Ratio18.44N/AN/AN/AN/A
P/E Growth9.34N/AN/AN/AN/A
Net Margins33.06%N/AN/AN/A-110.52%
Return on Equity (ROE)90.98%-10.72%N/AN/A-23.56%
Return on Assets (ROA)27.33%-10.40%N/AN/A-16.69%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio1.58%N/AN/AN/A0.10%
Current Ratio5.45%39.96%18.30%10.12%6.11%
Quick Ratio5.18%39.96%18.30%10.12%6.00%
Ownership Information
Institutional Ownership PercentageN/A73.05%67.59%74.08%33.30%
Insider Ownership Percentage15.86%27.40%N/AN/A16.41%
Miscellaneous
Employees306512043253
Shares Outstanding72.05 million19.71 million45.92 million50.95 million42.49 million
Next Earnings Date2/24/2021 (Confirmed)3/9/2021 (Estimated)3/2/2021 (Estimated)2/25/2021 (Estimated)3/3/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableOptionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.